glp 1 drugs and thyroid Hashimoto's GLP-1: what patients need to know before starting GLP-1 Meds Not Linked to

The key word in the safety data is "no increase in serious cardiovascular events." That said, the absence of evidence is not evidence of absence

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials

Tuttle KR, Bakris GL, Bilous RW, et al

MASH is a leading cause of liver transplantation

These appetite-suppressing effects have contributed to the increasing use of GLP-1RAs in obesity management [57,58]

The liver is being told to burn fat from two directions: indirectly through reduced caloric intake and improved metabolism, and directly through glucagon receptor mediated fat oxidation